Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2008

Karo Bio and Zydus Cadila Enter Inflammatory Disease Partnership

  • Karo Bio and Zydus Cadila are working together to discover and develop selective glucocorticoid receptor modulators for the treatment of inflammatory diseases.

    Under the three-year research collaboration Karo Bio will utilize its expertise in nuclear receptor drug discovery including structural biology, drug design, and compound characterization. Zydus Cadila will initiate a focused drug discovery and development program, undertaking preclinical studies, IND application filing, and clinical trials.

    Both parties will equally share the costs and and rewards from this partnership.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »